- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 21.11. | Early planning, outsourcing and digitalisation to break down CGT CMC barriers | ||
| 21.11. | Aspen closes $115m in Series C to advance Parkinson's cell therapy | ||
| 21.11. | Alvotech and Advanz announce EC approval for Gobivaz biosimilar | ||
| 20.11. | CPHI 2025: linker innovation paves the way for a wave of new ADCs | ||
| 20.11. | Merck KGaA eyes new Parkinson's disease assets with $3bn Valo partnership | ||
| 20.11. | Moderna to onshore drug product manufacturing to Massachusetts | ||
| 20.11. | Regeneron's Eylea franchise boosted by pair of FDA approvals | ||
| 20.11. | Novartis taps North Carolina as new manufacturing hub location | ||
| 20.11. | Pfizer and Tris agree with Texas over ADHD drug allegations | ||
| 20.11. | EC authorises Roche's Lunsumio SC for follicular lymphoma | ||
| 19.11. | Alkermes prevails over Lundbeck in Avadel bidding war | ||
| 19.11. | Arrowhead nets first commercial win as siRNA drug garners FDA approval | ||
| 19.11. | FDA approves AbbVie's Epkinly to treat follicular lymphoma | ||
| 19.11. | CSL to pump $1.5bn into US plasma supply chain | ||
| 19.11. | USPTO grants patent to Genprex's Reqorsa gene therapy | ||
| 19.11. | Insmed receives EC approval for Brinsupri to treat NCFB | ||
| 18.11. | Redefining clinical trials in oncology and rare diseases across the Europe | ||
| 18.11. | Solve Therapeutics raises $120m as MSD joins list of backers | ||
| 18.11. | Merus and Halozyme link on subcutaneous petosemtamab | ||
| 18.11. | Johnson & Johnson to acquire Halda Therapeutics for $3.05bn | ||
| 17.11. | Henlius and Organon score first US Perjeta biosimilar approval | ||
| 17.11. | High-dose Spinraza inches closer to EU approval despite FDA setback | ||
| 17.11. | Medicxi unveils €500m fund for asset-centric biotechs | ||
| 17.11. | FDA approves Sarepta's updated Elevidys label for DMD | ||
| 17.11. | Sofinnova closes €650m healthcare fund for early-stage ventures |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .